Biricodar

Biricodar
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • 1,7-di(pyridin-3-yl)heptan-4-yl (2S)-1-[oxo(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC34H41N3O7
Molar mass603.716 g·mol−1
3D model (JSmol)
SMILES
  • O=C(C(=O)c1cc(OC)c(OC)c(OC)c1)N4[C@H](C(=O)OC(CCCc2cccnc2)CCCc3cccnc3)CCCC4
InChI
  • InChI=1S/C34H41N3O7/c1-41-29-20-26(21-30(42-2)32(29)43-3)31(38)33(39)37-19-5-4-16-28(37)34(40)44-27(14-6-10-24-12-8-17-35-22-24)15-7-11-25-13-9-18-36-23-25/h8-9,12-13,17-18,20-23,27-28H,4-7,10-11,14-16,19H2,1-3H3/t28-/m0/s1 checkY
  • Key:CGVWPQOFHSAKRR-NDEPHWFRSA-N checkY
  (verify)

Biricodar or incel (INN, codename VX-710) was a pharmaceutical drug under development by Vertex Pharmaceuticals to help treat ovarian cancer patients, that never reached the market.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.